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The MX-Helix of Muscle nAChR
Subunits Regulates Receptor
Assembly and Surface Trafficking
Jolene Chang Rudell1†, Lucia Soares Borges1, Vladimir Yarov-Yarovoy1 and
Michael Ferns1,2*
1 Department of Physiology and Membrane Biology, University of California, Davis, Davis, CA, United States, 2 Department
of Anesthesiology and Pain Medicine, University of California, Davis, Davis, CA, United States
Nicotinic acetylcholine receptors (AChRs) are pentameric channels that mediate fast
transmission at the neuromuscular junction (NMJ) and defects in receptor expression
underlie neuromuscular disorders such as myasthenia gravis and congenital myasthenic
syndrome (CMS). Nicotinic receptor expression at the NMJ is tightly regulated and we
previously identified novel Golgi-retention signals in the β and δ subunit cytoplasmic
loops that regulate trafficking of the receptor to the cell surface. Here, we show that
the Golgi retention motifs are localized in the MX-helix, a juxta-membrane alpha-helix
present in the proximal cytoplasmic loop of receptor subunits, which was defined
in recent crystal structures of cys-loop receptor family members. First, mutational
analysis of CD4-MX-helix chimeric proteins showed that the Golgi retention signal was
dependent on both the amphipathic nature of the MX-helix and on specific lysine
residues (βK353 and δK351). Moreover, retention was associated with ubiquitination of
the lysines, and βK353R and δK351R mutations reduced ubiquitination and increased
surface expression of CD4-β and δ MX-helix chimeric proteins. Second, mutation of
these lysines in intact β and δ subunits perturbed Golgi-based glycosylation and surface
trafficking of the AChR. Notably, combined βK353R and δK351R mutations increased
the amount of surface AChR with immature forms of glycosylation, consistent with
decreased Golgi retention and processing. Third, we found that previously identified
CMS mutations in the ε subunit MX-helix decreased receptor assembly and surface
levels, as did an analogous mutation introduced into the β subunit MX-helix. Together,
these findings indicate that the subunit MX-helix contributes to receptor assembly and
is required for normal expression of the AChR and function of the NMJ. In addition,
specific determinants in the β and δ subunit MX-helix contribute to quality control of
AChR expression by intracellular retention and ubiquitination of unassembled subunits,
and by facilitating the appropriate glycosylation of assembled surface AChR.
Keywords: nicotinic acetylcholine receptor, protein motif, trafficking, neuromuscular junction, congenital
myasthenic syndrome
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INTRODUCTION
The muscle nicotinic acetylcholine receptor (AChR) is a ligand-
gated ion channel belonging to the cys-loop superfamily of
receptors that includes the neuronal ACh, GABAA, glycine and
5HT3 receptors. The muscle AChR mediates fast transmission
at the neuromuscular junction (NMJ) and is a pentamer
composed of four subunits with the stoichiometry α2βεδ (adult
form). All of the receptor subunits are homologous and have
a large extracellular N-terminal domain, 4 transmembrane
domains and a large cytoplasmic loop between transmembrane
domains 3 and 4 (Unwin, 2005; Sine, 2012). High resolution
structures have recently been obtained for several members
of the cys-loop family and reveal a conserved architecture of
the channel and constituent subunits, as well as providing
new insights into the structural basis of transmitter binding
and channel gating (Unwin, 2005; Hassaine et al., 2014; Miller
and Aricescu, 2014; Huang et al., 2015; Wu et al., 2015;
Morales-Perez et al., 2016). One region that is only partially
resolved in these structures, however, is the subunit large
cytoplasmic loop domain, which contains critical determinants
for trafficking and targeting of the receptor (Millar and
Harkness, 2008; Albuquerque et al., 2009). This region begins
with the short MX helix located just after TM3 and ends
with the long MA helix that is continuous with TM4,
but no structure is available for the intervening sequence
(Wu et al., 2015).
Synaptic transmission at the NMJ is rapid and reliable
due in part to the high density of AChRs in the postsynaptic
membrane, and defects in AChR expression in genetic and
autoimmune diseases impair transmission and result in
myasthenia (Verschuuren et al., 2016; Engel, 2018). The
expression of AChR at the NMJ is tightly regulated and depends
on the appropriate assembly, trafficking and localization of
receptors in the postsynaptic membrane (Millar and Harkness,
2008). This slow and complex process begins with the synthesis
and assembly of receptor subunits in the ER. Assembled receptor
is then exported from the endoplasmic reticulum (ER) and
trafficked to the Golgi apparatus for further processing, which
includes modification of N-linked oligosaccharides on the
γ and δ subunit to more complex forms (Gu et al., 1989; St
John, 2009). Finally, the mature AChR is sorted, trafficked
to the plasma membrane, and localized in the postsynaptic
membrane. Each step in this process is thought to be directed by
specific molecular signals in the receptor subunits that function
in distinct cellular compartments. Moreover, as the process
is relatively inefficient with only 10–30% of the synthesized
subunits being incorporated into surface nAChR (Merlie and
Lindstrom, 1983; Wanamaker et al., 2003), quality control
mechanisms play an important role in ensuring that only
correctly assembled, functional channels are expressed on the
cell surface (Fu et al., 2016).
The molecular basis for the initial steps in AChR biogenesis
are relatively well understood, with several signals being defined
on the receptor subunits that govern receptor assembly and
ER quality control (Millar and Harkness, 2008; Colombo et al.,
2013). For example, determinants in the subunit extracellular
domains direct the ordered assembly of receptor subunits,
helping ensure the correct stoichiometry of receptor. Other
determinants in the subunit first transmembrane domain
and major cytoplasmic loop permit the export of pentameric
receptor from the ER, but retain unassembled or partially
assembled subunits (Keller et al., 2001; Wang et al., 2002;
Ren et al., 2005), where they are then ubiquitinated and
degraded by the ER-associated degradation machinery
(Christianson and Green, 2004). In contrast, little is known
about the molecular signals that regulate subsequent steps
in AChR trafficking. Golgi trafficking is likely regulated, as a
genetic screen in Caenorhabditis elegans identified the Golgi-
resident protein, unc-50, as being required for trafficking
of one subtype of nAChR to the NMJ (Eimer et al., 2007).
Moreover, it likely provides an additional quality control
checkpoint, as mutations in the α subunit loop that allow ER
export result in the unassembled subunit being retained in
the Golgi by an unknown mechanism (Keller et al., 2001).
To define the molecular determinants that regulate these
later trafficking steps we performed an unbiased screen
for post-ER trafficking signals in the AChR subunit major
cytoplasmic loop. We identified novel motifs in the β and
δ subunit loops that mediate Golgi retention, and mutation
of this motif permits surface expression of unassembled
subunit loops and increases surface levels of assembled
AChR (Rudell et al., 2014). Here, we show that the Golgi
retention signal is localized in the MX-alpha helix and is
centered on key lysine residues. We find that the motif
contributes to quality control both through ubiquitination
and intracellular retention of unassembled subunits, and
by facilitating the appropriate Golgi-based glycosylation
of assembled receptor. In addition, we identify distinct
determinants in the MX helix that contribute to receptor
assembly, and CMS-linked mutations in this region impair
subunit assembly and AChR expression. Thus, the MX-helix
of receptor subunits contain important molecular signals that
regulate the assembly, trafficking and expression of muscle
AChR at the NMJ.
MATERIALS AND METHODS
Rosetta Molecular Modeling
Homology modeling of human AChR beta and delta subunits
was performed using Rosetta structural modeling software (Rohl
et al., 2004; Song et al., 2013; Bender et al., 2016; Alford
et al., 2017) based Robetta server (Park et al., 2018) and
x-ray structure of the human alpha4beta2 nicotinic receptor
(Morales-Perez et al., 2016) as a template. Human AChR
beta subunit was modeled based on human alpha4beta2
nicotinic receptor beta 2 subunit (PDB ID: 5KXI chain C)
(Morales-Perez et al., 2016). Human AChR delta subunit was
modeled based on human alpha4beta2 nicotinic receptor beta
2 subunit (PDB ID: 5KXI chain B) (Morales-Perez et al.,
2016). 1,000 models were generated for each subunit and
clustered (Bonneau et al., 2002) to identify top 5 models.
We then superimposed a representative model from one of
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the top human AChR beta subunit models onto human
alpha4beta2 nicotinic receptor beta 2 subunit (PDB ID: 5KXI
chain C) and a representative model from one of the top
human AChR delta subunit models onto human alpha4beta2
nicotinic receptor beta 2 subunit (PDB ID: 5KXI chain
B) in the complete structure of the human alpha4beta2
nicotinic receptor (Morales-Perez et al., 2016). All structural
figures were generated using the UCSF Chimera package
(Pettersen et al., 2004).
CD4-Subunit Loop Constructs
Chimeric constructs consisting of mouse CD4 extracellular and
transmembrane domains fused with the major cytoplasmic loop
of each mouse nAChR subunit were generated and described
previously (Borges et al., 2008; Rudell et al., 2014). Mutations in
the intracellular loops were introduced using the QuikChange
Lightning site-directed mutagenesis kit (Agilent Tech.) and
confirmed by sequencing.
Cell Culture and Transfection
HEK cells were maintained in growth media (DMEM
supplemented with 10% fetal bovine serum, 2 mM L-glutamine
and 200 U/ml penicillin-streptomycin) at 37◦C and 5%
CO2. They were transfected at ∼70% confluence using
calcium phosphate (for large 10 cm dishes) or Lipofectamine
3000 (Invitrogen).
C2 mouse muscle cells were maintained in growth media
(DMEM supplemented with 20% fetal bovine serum, 0.5% chick
embryo extract, 2 mM L-glutamine and 200 U/ml penicillin-
streptomycin) at 37◦C and 8% CO2. Myoblasts were transfected
at ∼60–70% confluence using Fugene (Roche) or Lipofectamine
3000 (Invitrogen). Upon reaching confluence the cells were
incubated with fusion medium (DMEM supplemented with 5%
horse serum and 2 mM L-glutamine) and allowed to differentiate
into myotubes for 3–4 days prior to analysis (Borges et al., 2008).
Surface Expression of CD4 Chimeras
and AChR
For on cell western assays, C2 muscle cells were grown on
8-well chamber slides and duplicate wells were transfected
with each CD4-subunit loop chimera. After 3–4 days for
expression the cells were fixed and one of the two wells
was permeabilized with 0.5% Triton X-100. The slides were
then incubated with anti-CD4 antibody to assay surface
levels of CD4-chimera in non-permeabilized cells (first well),
compared to total levels (surface + intracellular) of the
same CD4-chimera in permeabilized cells (second well).
Bound antibodies were detected using IRDye-conjugated anti-
rat secondary antibodies and an Odyssey Imaging System
(LiCor). Total signal intensity was measured for each well
and the percentage of surface (non-permeabilized) versus total
(permeabilized) expression calculated for each CD4-subunit loop
chimera. Data was collected from 4–6 independent experiments
for each construct.
To assay levels of surface AChR, HEK cells were grown on
6-well plates and transfected with mouse AChR subunits. After
1 d for expression, the cells were labeled with 10 nM I125-
labeled-α-BuTx (Perkin Elmer) for 45 min. Non-specific binding
was determined by treating myotubes with 1 µM of cold α-
BuTx for 30 min prior to incubation with I125-α-BuTx. Cells
were then washed three times with growth media to remove
unbound I125-α-BuTx, solubilized in 0.1N NaOH and the I125-
α-BuTx bound to surface AChR was measured with a Packard
gamma counter. Background counts were subtracted from the
experimental counts and values are reported as a percentage of
the total surface counts for cells transfected with wild type AChR.
Isolation and Immunoblotting of
CD4-Chimeras and AChR
To assay ubiquitination of CD4 subunit loop chimeras by
western blotting, transfected C2 muscle cells were washed,
scraped off and pelleted in ice cold PBS. They were then re-
suspended in extraction buffer (0.5% Triton X-100, 25 mM Tris,
25 mM glycine, 150 mM NaCl, 5 mM EDTA, and protease
inhibitors) and incubated for 10 min on ice, after which the
insoluble proteins were pelleted by centrifugation at 13,000 rpm
for 5 min. The CD4 chimeras were immunoprecipitated
from the soluble fraction with monoclonal antibody GK1.5
(BD Biosciences-Pharmingen, San Jose, CA) chemically cross-
linked to protein G-agarose (Invitrogen, Carlsbad, CA). The
isolates were separated on 10% polyacrylamide gels and
immunoblotted with anti-ubiquitin antibody P4D1 (Santa Cruz
Biotech.). The bound antibodies were then detected using IRDye-
conjugated secondary antibody, imaged with an Odyssey Imaging
System, and band intensities quantified using ImageStudio
(Li-Cor). Immunoblots were re-probed with rmCD4 antibody
(R&D Systems) to confirm levels of the different CD4
subunit loop chimeras.
To assay AChR glycosylation, heterologous HEK cells were
transfected with wild type or mutant AChR subunits. Epitope
tagged (142) delta subunits were used to allow unambiguous
identification of delta, and G1G2 delta variants had T78A and
S145A mutations to eliminate the two N-linked glycosylation
sites (Ramanathan and Hall, 1999). After 1 day for expression,
the cells were incubated live with biotinylated α-bungarotoxin
(α-BuTx) for 45 min to label surface AChR, and then washed,
collected and extracted in buffer containing 0.5% Triton
X-100, 25 mM Tris, 25 mM glycine, 150 mM NaCl, 5 mM
EDTA and Halt protease inhibitor cocktail (ThermoScientific).
First, biotin-α-BuTx-labeled surface receptor was isolated
from the extracts using streptavidin-beads (Invitrogen).
Then, unlabeled intracellular AChR was isolated from the
remaining supernatant by re-incubation with biotin-α-BuTX
and pulldown on streptavidin beads. The samples were separated
on large format 10% polyacrylamide gels (14 × 14 cm) and
immuno-blotted with anti-β (mAb148) and anti-δ (mAb142)
subunit antibodies (Santa Cruz Biotech.). Bound antibodies
were detected using IRDye-conjugated anti-rat secondary
antibody, imaged with an Odyssey Imaging System, and
band intensities quantified using ImageStudio (Li-Cor). In
experiments to assay AChR assembly, unassembled β subunit
was isolated from cell extracts after isolation of assembled
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AChR, using mAb148 chemically cross-linked to protein
G-agarose.
RESULTS
Molecular Structure and Determinants of
MX-Helix Retention Motifs
In previous work we identified Golgi retention motifs in the β
and δ subunit proximal cytoplasmic loops (Rudell et al., 2014).
Interestingly, this region corresponds to the MX-helix, which is
a juxta-membrane amphipathic α-helix defined in recent crystal
structures of cys-loop receptor family members (Hassaine et al.,
2014; Morales-Perez et al., 2016). As this region is not resolved
in the lower resolution structures of the muscle AChR (Unwin,
2005), we used Rosetta software to model the MX-helices using
the neuronal α4β2 AChR crystal structure (Morales-Perez et al.,
2016). As shown in Figures 1A–C, the structure and position
of the MX-helix is similar in all subunits, although differences
exist in the distribution of charged residues. In the case of
the β and δ subunits, the Golgi retention motifs consist of a
short loop following TM3 and the laterally positioned MX-helix
FIGURE 1 | Golgi retention motifs are localized in the MX-helix. (A) Sequence alignment of the neuronal beta 2 and muscle beta and delta subunits, depicting the
initial portion of the large cytoplasmic (TM3-TM4) loop. The MX-helix region is shown by the gray box, and the Golgi retention signals in β and δ are both centered on
lysine residues (βK353 and δK351; denoted by red boxes). Sequence identity and conservation are represented by * and : symbols. (B) General architecture of the
nicotinic acetylcholine receptor, based on the α4β2 crystal structure, showing the extracellular (EC), transmembrane (TM), and intracellular (IC) domains. Alpha
subunits are in light gray, beta subunit in green, delta subunit in blue and epsilon subunit in light blue. The arrow marks the δ subunit MX-alpha helix, which is
positioned laterally just below the membrane. Note that the rest of the intracellular domain is missing from the structure. (C) View perpendicular to the membrane
looking from the intracellular side. Asterisks mark the MX-helix in each subunit. (D) The muscle beta and delta subunits were modeled using Rosetta structural
modeling software. The initial portion of the TM3-TM4 cytoplasmic segment consists of a short loop following TM3 (arrowhead) followed by the laterally positioned
MX-helix (residues shown with sidechains). The MX-helix contains the critical determinants for the Golgi retention signal, which are centered around K353 in the beta
subunit and K351 in the delta subunit (red arrows mark key lysine residues, which are shown in space filling representation).
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(Figure 1D). The key sequence determinants for retention
identified in our earlier study lie within the MX-helix and
include an ordered sequence of hydrophobic and hydrophilic
residues related to the partially amphipathic structure of the
helix. Moreover, the critical lysine residues identified in the β
and δ motifs (βK353 and δK351) are both surface-exposed in
the model and potentially accessible, although the sidechains of
βK353 are positioned close to the plasma membrane (Figure 1D).
This MX helix structure provides a straightforward molecular
basis for the functional effects described in our earlier mutational
analysis (Rudell et al., 2014). For example, βK353L and δK351L
mutations would locally alter the surface charge on the MX-helix,
and other single amino-acid insertions or deletions that abolished
retention (e.g., βQ348del, βL353ins, and δK354ins) would shift
the rotational axis of the helix and also alter the relative
position of the charged and hydrophobic residues. Together, this
structural and functional analysis indicates that β and δ subunit
trafficking motifs depend on the alpha-helical MX structure and
its distribution of charged and hydrophobic residues.
Although all receptor subunits possess an MX-helix one
feature of the β and δ subunits is the surface-exposed lysine
residues (βK353 and δK351). To further probe their role in
the retention signal, we compared the effects of mutating the
lysine residues to either leucine or arginine. Substitution to
leucine preserves the MX α-helical structure but replaces the
positively charged lysine residue with a neutral amino acid,
whereas substitution to arginine maintains the positively charged
residue and thus the alignment of charged amino acids on the
helix. For this, we expressed CD4-subunit loop chimeric proteins
in C2 mouse muscle cells and used an on-cell western assay
to quantify surface versus total expression for each chimera
(Supplementary Figure 1). As shown in Figure 2A, the chimeras
consist of the CD4 extracellular and transmembrane domains
fused to the β or δ cytoplasmic loops, or to the minimal β or
δ retention signals encompassing the MX-helix. As reported in
our earlier study, a large fraction of CD4-β and δ loop chimeras
were retained intracellularly, but mutating the key lysine residue
in each motif to leucine (βK353L or δK351L) was sufficient to
increase their surface expression several-fold (Rudell et al., 2014).
Surprisingly, we found that lysine to arginine mutations also
significantly increased their surface expression (Figure 2B), with
surface levels approaching those of CD4-loop chimeras with K-L
mutations. Indeed, β K353L and K353R mutations increased
surface levels of CD4-β loop by 5.9 and 3.6-fold, and CD4-
β333-369 by 3.2 and 2.5-fold, respectively. Similarly, δ K351L
and K351R mutations increased surface levels of CD4-δ loop by
98 and 77-fold, and CD4-δ337-370 by 2.2 and 2.9-fold. These
experiments indicate that the β and δ retention signals depend
not only on the amphipathic nature of the MX-helix, but also on
specific lysine residues (βK353 and δ K351).
Role of the MX-Helix Retention Motifs in
Quality Control
Lysine residues are notable in that they are targets for several
types of post-translational modification. The most common is
ubiquitination, which plays an important role in the regulation of
trafficking, degradation and quality control of many membrane
proteins (Mukhopadhyay and Riezman, 2007; MacGurn et al.,
2012; Foot et al., 2017). Consequently, we tested whether MX-
helix lysine residues are ubiquitinated and if ubiquitination
contributes to retention. For this, we expressed CD4-subunit
loops in HEK cells as the low expression levels of some chimeras
in muscle cells was prohibitive for biochemical experiments.
The CD4-subunit loop chimeras were then immunoprecipitated
from cell extracts using anti-CD4 antibody and immunoblotted
with anti-ubiquitin antibody. Notably, we detected significant
ubiquitination of CD4-β and δ loops but low or undetectable
ubiquitination of CD4 or CD4-ε loops (Figure 3A). The
ubiquitination of CD4-β and δ loops was evident as a higher
molecular weight ladder beginning around 9 kD above the major
CD4-β and δ bands detected with anti-CD4 antibody, consistent
with the addition of one or more ubiquitin molecules. Thus,
ubiquitination occurs on CD4-β and δ loops which are retained
intracellularly, but not on CD4 and CD4-ε loop, which are
trafficked efficiently to the cell surface.
To then define the determinants for ubiquitination, we
expressed CD4-β and δ proximal loop fragments with mutations
of βK353 and δK351 or of neighboring residues. We detected
robust ubiquitination of CD4-β333-369, which was significantly
reduced by mutation of K353 to either L or R (Figure 3B).
Similarly, ubiquitination of CD4-δ337-370 was largely abolished
by mutation of K351 to L or R and comparable to CD4 control
(Figures 3B,C). In addition, we tested whether other mutations
previously found to impair retention of CD4-β333-369 also
reduced ubiquitination. Indeed, insertion of a leucine in the MX
helix (L353ins) or substitution of L354 for lysine both greatly
decreased ubiquitination, despite the presence of K353 or even
an additional lysine. Finally, by immunoblotting with anti-CD4
antibody we confirmed that the differing levels of ubiquitination
were unrelated to total expression of CD4-β333-369 and δ337-
370, and also that only a small proportion of each occurred in
the higher molecular weight, ubiquitinated form. Together, these
findings suggest that ubiquitination occurs largely on βK353
and δK351 and is dependent on a specific recognition sequence
that encompasses these lysines in the MX-helix. Ubiquitination
correlates closely with intracellular retention of the CD4-β and
δ loop chimeras, and likely regulates either their retention in
the Golgi apparatus and/or their subsequent degradation. Thus,
ubiquitination of the MX-helix motifs contributes to Golgi-based
quality control of receptor trafficking.
Next, we tested whether the Golgi retention motifs also
regulate trafficking and quality control of fully assembled AChR.
For this, we focused on glycosylation of the AChR, which
includes a key maturational step that occurs in the Golgi
apparatus. Previous studies have shown all receptor subunits
contain conserved N-linked glycosylation sites mostly with
simple oligosaccharides added during receptor biosynthesis in
the ER (Gehle et al., 1997). In the case of the gamma and delta
subunits, however, the simple oligosaccharides at one of the
glycosylation sites are modified to complex forms in the Golgi
apparatus (Gu and Hall, 1988; Ramanathan and Hall, 1999),
prior to receptor trafficking to the plasma membrane. First,
to confirm the earlier studies, we sequentially isolated surface
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FIGURE 2 | Molecular determinants for retention include specific lysine residues. (A) Schematic showing the CD4-subunit cytoplasmic loop chimeras used to
characterize the retention signal. These consist of CD4 extracellular and transmembrane domains fused to either the full β or δ subunit intracellular loops, or to
proximal loop fragments encompassing the MX-helix. (B) C2 mouse muscle cells were transfected in duplicate with each CD4-subunit loop chimera, and the
percentage of each protein that was expressed on the cell surface was measured in on-cell Western blot assays. The percentage of CD4-β and δ full loops and
CD4-β333-369 and δ337-370 on the cell surface (gray bars) was much lower than for CD4 control (hatched bar). Surface expression of the CD4-β and δ chimeras
was increased significantly, however, by substitution of βK353 or δK351 for either leucine or arginine (**p < 0.01;*p < 0.05; one way ANOVA with Tukey’s multiple
comparisons test; n = 4–6 experiments, error bars = SEM). The effect of K–L mutations tended to be slightly larger than K–R mutations, but this difference was not
statistically significant.
and intracellular AChR from transfected HEK cells (see section
“Methods”), and then immunoblotted for the β and δ subunits
(Figure 4A). To unambiguously identify the δ subunit we utilized
an antibody to a C-terminal epitope tag, as available antibodies
recognize both the γ and δ subunits. We found that the wild
type (WT) δ subunit in surface AChR runs at significantly higher
molecular weight than δ in intracellular AChR (∼68 cf. 62 kD),
confirming that its N-linked oligosaccharides are modified prior
to trafficking to the plasma membrane. Indeed, quantification
of these experiments shows that ∼90% of the delta subunit in
surface AChR has mature glycosylation, compared to only 17%
in intracellular receptor (Figure 4B). To confirm that the shift
in molecular weight was due to changes in glycosylation we
expressed AChR containing delta subunit with mutations of the
glycosylation sites (δG1G2). As expected, deltaG1G2 was evident
as a single band of lower molecular weight and present only
in intracellular receptor (Figure 4A). Similarly, expression of
an incomplete set of receptor subunits (α, β, and δ subunits)
resulted in delta subunit with largely immature glycosylation
and mostly in intracellular receptor. These findings confirm
earlier studies and show that N-linked glycosylation of the delta
subunit is required for efficient subunit assembly and surface
expression of AChR.
We have shown previously that mutation of the retention
motifs increases surface AChR by promoting Golgi to surface
trafficking (Rudell et al., 2014). Consequently, we tested whether
the β/δ retention motifs contribute to delta subunit glycosylation
in the Golgi and if their mutation perturbs the selective
expression of mature AChR on the cell surface. To do this,
we expressed AChR in wild type form or with combined
βK353L and δK351L mutations, and sequentially isolated surface
and intracellular receptor and then immunoblotted for the
β and δ subunits. We found that surface wild type and
mutant AChR contained predominantly the high molecular form
of the delta subunit with mature glycosylation. However, a
significantly higher percentage of low molecular weight delta
subunit was detected in βK353L/δK351L – AChR compared
to wild type AChR (16% cf. 8%, Figures 4C,D). Thus,
mutation of the retention motifs increases surface AChR
with immature glycosylation by twofold, indicating that the
motifs contribute to Golgi trafficking and quality control of
assembled receptor.
Role of MX-Helix in AChR Assembly and
Expression
The MX-helix is present in all receptor subunits and could
regulate additional aspects of AChR assembly or trafficking
that are critical for its expression and function at the NMJ.
Consistent with this, two previously identified human mutations
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FIGURE 3 | Retention is associated with ubiquitination of MX-helix lysine residues. (A,B) CD4 subunit loop chimeras expressed in HEK cells were
immunoprecipitated from cell extracts using anti-CD4 antibody cross-liked to agarose beads. The isolates were immunoblotted with monoclonal anti-ubiquitin
antibody (P4D1), and then re-probed with polyclonal anti-CD4 antibody. We detected ubiquitination of both CD4-β and δ full loops (A) and CD4-β333-369 and
δ337-370 MX-helix chimeras (B). The ubiquitination was evident as a characteristic ladder of high molecular weight forms (bracket) beginning around 9 kD above the
major band detected with anti-CD4 antibody (arrow). In contrast, little or no ubiquitination was evident for CD4 (control), CD4 with a deleted intracellular tail (CD4-T),
or CD4-ε loop. Note that the asterisk marks a non-specific band present in non-transfected samples. (B) High levels of ubiquitination of CD4-β333-369 and
δ337-370 were greatly reduced by mutation of βK353 or δK351 to either leucine (L) or arginine (R). Mutations adjacent to βK353 also reduced ubiquitination
(βL353ins and βL354K). (C) Quantification of the immunoblots shows that ubiquitination of CD4-β333-369 was reduced 57% by K353L/R mutations, and
ubiquitination of CD4-δ337-370 was reduced 92% by K351L/R mutations (***p < 0.001, one way ANOVA with Tukey’s multiple comparison’s test, n = 4–6
independent transfection experiments).
linked to congenital myasthenic syndrome (CMS) localize to the
epsilon subunit MX-helix. The first is a homozygous missense
mutation (CHRNE P351L; Croxen et al., 2001), which reduces
assembly and surface expression of AChR in heterologous
cells, and the second is a homozygous 27 base pair deletion
(CHRNE 1046_1072del27 eliminating amino acids 349-357),
whose functional effects are uncharacterized (Maselli et al.,
2010). Interestingly, these mutations occur near the end of the
MX helix (Figure 5A) and the structural model shows that
these residues contribute to the cytoplasmic interface between
the α and ε subunits (Figure 5B). Indeed, in the molecular
structures of both the α4β2 and 5HT3 receptors, the end of
each subunit MX-helix contacts the short loop following TM3
in the adjacent subunit (Hassaine et al., 2014; Morales-Perez
et al., 2016). These findings suggest that the MX-helix could
play a role in subunit assembly and AChR expression. To test
this, we compared the effects of the CMS-linked mutations
in both the epsilon and beta subunits. For this, wild type
and mutant AChR subunits (α, β, ε, and δ) were expressed
in heterologous HEK cells, and levels of surface receptor
were measured by binding of I125-labeled alpha-bungarotoxin.
Compared to wild type AChR, we found that surface receptor
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FIGURE 4 | Mutation of the Golgi retention motif increases surface AChR with immature glycosylation. (A) HEK cells were transfected with wild type AChR subunits
(α, β, ε, and an epitope-tagged δ subunit), or with AChR containing δ subunit with mutated N-linked glycosylation sites. We then sequentially isolated surface and
intracellular AChR and immunoblotted the isolates for the β and δ subunits. We found that surface AChR contained a higher molecular weight form of δ subunit
compared to intracellular AChR (∼68 cf. 62 kD), which has been shown to be due to modification of N-linked oligosaccharides during transit through the Golgi
complex. Consistent with this, AChR containing δ with mutated glycosylation sites (δG1G2), or only α, β and δ subunits were largely retained in the intracellular
receptor pool and contained only lower molecular weight forms of δ (marked by asterisks in longer exposure image). (B) Quantification shows that surface AChR
contains largely high molecular weight δ subunit with mature glycosylation (89% of total). In contrast, intracellular AChR contains only 17% high molecular weight δ
subunit, with the vast majority (83%) being low molecular weight δ subunit with immature glycosylation (**p < 0.005; paired t test; n = 5 experiments; error
bars = SEM). (C) HEK cells were transfected with wild type AChR or AChR containing combined βK353L and δK351L mutations (K–L), and surface and intracellular
AChR were sequentially isolated and immunoblotted with anti-β and δ subunit antibodies. Compared to wild type AChR, mutant AChR contained significantly more
low molecular weight delta subunit with immature glycosylation (asterisk). (D) Quantification showing the percentage of WT and K–L surface AChR with immature δ
subunit glycosylation, with each pair of data points representing a separate transfection experiment. Combined βK353L/δK351L mutations increased the amount of
surface AChR with immature glycosylation by twofold, from 8 to 16% (**p < 0.005; paired t-test; n = 5 experiments).
levels were decreased 25% for εP351L-AChR and 55% for
εdel349-357-AChR (Figure 5C). An analogous mutation in
the β subunit (βP355L) decreased receptor levels by 50%, but
a βP355A mutation had no discernable effect. In addition,
we found that a targeted mutation of the preceding residue
(βL354K) designed to misposition the MX-helix reduced surface
receptor levels by 85%. In the case of CHRNE P351L, the
decrease in surface receptor results primarily from impaired
assembly of the mutant subunit (Croxen et al., 2001). To
test whether this is also the case for βP355L we sequentially
isolated assembled AChR and then unassembled beta subunit
and immunoblotted to compare the amount of beta subunit
in each pool (Figure 5D). Notably, βP355L subunit assembled
into AChR much less efficiently than wild type β subunit
(Figure 5E). Together, these findings show that CMS mutations
in the epsilon subunit and analogous mutations in the beta
subunit both reduce surface expression of the AChR, in large
part by impairing subunit assembly. Thus, the MX-helix also
contains shared determinants that contribute to subunit assembly
and AChR expression.
DISCUSSION
AChR function at the NMJ depends on its appropriate
assembly, processing and trafficking to the cell surface, with
each step in receptor biogenesis being regulated by specific
molecular determinants in the receptor subunits. Here, we
identify important regulatory signals localized in the MX-helix,
which is a juxta-membrane α-helix present in the proximal,
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FIGURE 5 | CMS-linked mutations in the MX-helix impair AChR assembly and expression. (A) Sequence alignment showing the initial portion of the beta and epsilon
cytoplasmic (TM3-TM4) loops, with the MX-helix shown by the gray box. The two CMS-linked mutations in the epsilon subunit are denoted by the red box (εP351L)
and orange line (εdel349-357), respectively. The analogous proline in the β subunit MX-helix (βP355L) is indicated by the red box. (B) Molecular structure showing the
cytoplasmic interface between the alpha and epsilon subunits. The end of the ε MX helix contacts the short loop connecting TM3 to the MX-helix of the α subunit.
Residues deleted in the εdel mutation are shown in orange and the εP351L mutation is marked by the red arrow. (C) HEK cells were transfected with AChR in wild
type form or with the indicated mutations in the MX-helix, and surface levels of AChR were measured by 125 I-alpha-BuTx binding. Compared to WT AChR, the
CMS-linked mutations in epsilon (εP351L and εdel349-357) decreased surface levels of AChR by 25 and 57%, respectively. The corresponding βP355L mutation
decreased surface AChR by 51% but βP355A mutation had no discernable effect. Beta L354K mutation, which is predicted to misposition the MX helix, decreased
surface AChR by 85% (***p < 0.0001 as compared to WT; one way ANOVA with Dunnett’s multiple comparison’s test; n = 3–8 experiments). (D) HEK cells were
transfected with wild type or βP355L-AChR. We then sequentially isolated surface AChR, intracellular AChR, and unassembled beta subunit, and immunoblotted
with anti-beta subunit antibody to compare the levels in each pool. Significant amounts of wild type β subunit were detected in the pools of surface and intracellular
AChR, as well as in the pool of unassembled subunit. In contrast, βP355L subunit was mostly detected in the unassembled subunit pool, indicating that it
assembled less efficiently into AChR. (E) Quantification shows that a smaller percentage of P355L β subunit (23%) assembled into AChR compared to wild type β
subunit (49%) (*p < 0.05, one way ANOVA with Sidak’s multiple comparison’s test, n = 3 experiments).
major cytoplasmic loop of all subunits. First, specific sequence
determinants in the β and δ subunit MX-helices mediate Golgi
retention and contribute to quality control of AChR expression
by (i) retention of unassembled subunit loops, leading to their
ubiquitination and degradation, and (ii) retention of assembled
AChR, helping ensure appropriate glycosylation occurs in
the Golgi prior to their surface trafficking. Second, shared
determinants in a distinct region of the subunit MX-helices
contribute to subunit assembly, as CMS and targeted mutations
near the end of the MX-helix impair receptor assembly and
surface expression.
Molecular Signals in MX Helix
The Golgi retention motifs that we previously identified in
the β and δ subunits reside in the MX-helix, which was
defined in crystal structures of both the α4β2 neuronal AChR
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and the 5HT3 receptor (Hassaine et al., 2014; Morales-Perez
et al., 2016). This juxta-membrane α-helix is present in all
subunits and is positioned laterally in the proximal TM3-TM4
cytoplasmic loop, placing it in close proximity to the inner
leaflet of the plasma membrane, and ending near the interface
with the adjacent receptor subunit. Using the neuronal α4β2
structure we generated a molecular model of the muscle β
and δ subunit motifs, whose structure readily accounts for
the sequence requirements for Golgi retention identified in
our earlier mutational analysis (Rudell et al., 2014). First, the
requirement for an ordered array of charged and hydrophobic
residues corresponds directly to the amphipathic nature of
the helix, and explains why single amino-acid insertions,
deletions, or substitutions of hydrophilic and hydrophobic
residues all reduced intracellular retention. Second, the critical
lysine residues in β and δ (βK353 and δK351) are both
surface exposed with outward-facing sidechains, whereas lysine
residues are absent at the equivalent positions in the other
subunits (α, γ, and ε). The importance of βK353 and δK351
is further underscored by our finding that even substitution
with another positively charged residue (arginine) significantly
reduced Golgi retention. Together with our earlier findings,
this suggests that the Golgi retention signal consists of a
short, solvent-exposed face of the MX-helix encompassing the
key lysine residue.
The MX-helix structure is conserved in all subunits of both
the α4β2 AChR and 5HT3 receptors, however, consistent with
additional functions in AChR assembly and function (Wu
et al., 2015). Indeed, we found that CMS-linked mutations in
epsilon (εP351L and εdel349-357) that reduce AChR assembly
and levels are located at the end of the MX-helix, and
our structural model shows that these residues contact the
initial portion of the alpha subunit TM3-TM4 loop. An
analogous P355L mutation in the β subunit MX-helix also
impaired subunit receptor assembly and expression (Figure 5),
whereas a P355A mutation had no detectable effect on either.
The reason for this remains unclear, but potentially the
longer sidechains of leucine could disrupt either the folding
and/or inter-subunit interactions of the beta subunit. Notably,
this proline residue is part of a highly conserved (L/I/V)P
sequence pair, which is present in almost all muscle and
neuronal AChR subunits and consequently could contribute
generally to the cytoplasmic interface between subunits and
their assembly. Moreover, we have shown previously that the
LP residues are not required determinants for the β/δ Golgi
retention signals (Rudell et al., 2014). Thus, these findings
define additional molecular determinants in the MX-helix
important for receptor assembly/expression, which map to
the end of the MX-helix and are distinct from the Golgi
retention signals.
Function and Mechanism of MX-Helix
Signals
The retention signals specific to the β/δ subunit MX-helix
regulate Golgi trafficking and we propose that they contribute
to quality control of AChR expression in two ways. First,
our findings suggest that the retention motifs help prevent
surface expression of unassembled or incorrectly assembled
receptor subunits that escape the ER quality control mechanisms.
The presence of an additional quality control checkpoint at
the Golgi complex has been documented in many systems
(Arvan et al., 2002; MacGurn et al., 2012), and some
studies have suggested such a checkpoint exists in AChR
trafficking to the cell surface (Keller et al., 2001; Zhao
et al., 2009; Rezvani et al., 2010; Crespi et al., 2018). The
Golgi-resident protein that binds the β/δ motifs remains
unknown, but is likely distinct from known proteins such
as unc-50 or VILIP which both promote Golgi to surface
trafficking of the receptor (Eimer et al., 2007; Zhao et al.,
2009). It is also unlikely to be the sorting receptor Rer1p,
which recognizes and retains unassembled α subunits (Valkova
et al., 2011), rather than a motif specific to the β and δ
subunits. The mechanism by which Golgi protein binding to
the β/δ motifs discriminates between unassembled subunits
and assembled receptor, and thereby provides quality control
also remains unclear. One possibility is that the motifs are
exposed in unassembled or incorrectly assembled subunits,
leading to binding and retention, but are partially masked or
regulated in correctly assembled receptor, permitting forward
trafficking to the plasma membrane. Masking could occur
through inter-subunit contacts or conformational changes
that reduce the accessibility of the motif. For example, our
molecular model suggests that appropriate assembly of the
β subunit into pentameric receptor would position βK353
close to the inner leaflet of the plasma membrane (see
Figure 1), which could potentially mask the β MX-helix
retention motif.
Additional support for a quality control function comes
from our finding that Golgi retention is associated with
ubiquitination of the β/δ MX-helix motifs. Indeed, we
observed robust and selective ubiquitination of CD4-β and
δ MX-helices, which was largely abolished by mutation
of the key lysine residues in each (βK353 and δK351).
Thus, we propose that these lysines are the predominant
sites of ubiquitination, and consistent with this, βK353
has been found to be ubiquitinated in proteomic studies
(Hornbeck et al., 2015). As point mutations of neighboring
residues also impaired ubiquitination, ubiquitination of
βK353 or δK351 likely involves recognition of a specific
amino-acid sequence by an E3 ubiquitin ligase. Potential
candidates are the E3 ligases PDZRN3, MuRF1, NEDD4,
and TRIM63, which have all been implicated in protein
turnover at the NMJ (Lu et al., 2007; Liu et al., 2009; Rudolf
et al., 2013; Khan et al., 2014). Golgi-based ubiquitination
has previously been shown to sort mis-folded proteins
into degradation pathways (MacGurn et al., 2012), and it
seems likely that ubiquitination of the MX-helix motifs
acts in a similar manner and targets unassembled or
incorrectly assembled subunits for degradation via either
the lysosomal or proteosomal pathways (Foot et al., 2017).
One key question, however, is whether ubiquitination is
the signal for retention, or a consequence of retention
that marks the proteins for degradation. We tend to favor
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the latter idea for several reasons: (i) in immunostaining
experiments we detected significant accumulation of CD4-β/δ
chimeras in the Golgi but no corresponding accumulation of
ubiquitinated protein; (ii) in immunoblotting experiments,
we found that only a small minority of CD4-β/δ chimeras
is ubiquitinated (i.e., evident as higher molecular weight
bands); and (iii) in immunostaining experiments we still
observed some accumulation of CD4-βK353R MX-helix
in the Golgi, despite little or no ubiquitination of this
chimera. Thus, we propose that unassembled or incorrectly
assembled subunits that escape the ER are retained in the
Golgi through recognition of the β/δ motifs by a Golgi-
resident protein and that this leads to their ubiquitination
and degradation.
Second, our findings demonstrate that the β/δ motifs
also contribute to quality control of assembled AChR by
regulating its glycosylation in the Golgi complex. After receptor
subunits are synthesized and assembled in the ER, the AChR
is trafficked to the Golgi complex for further processing,
which includes the modification of N-linked oligosaccharides
on the γ and δ subunits to more complex forms. This
process is normally highly efficient, as almost all surface
receptor contains delta subunit with mature glycosylation.
We found, however, that mutation of the β and δ subunit
retention motifs (with combined βK353L/δK351L mutations)
resulted in a significant 2-fold increase in the proportion
of surface receptor with immature glycosylation. Thus, we
propose that the β/δ motifs help retain the receptor in the
Golgi to allow for modification of the oligosaccharides to
complex forms. This is consistent with our earlier finding
that mutation of the β/δ motifs increased surface levels of
AChR (Rudell et al., 2014). Moreover, it implies that at least
one of the retention motifs remains accessible in assembled
AChR, although it may be regulated to permit Golgi to surface
trafficking. These findings define a second form of quality
control overseeing maturational steps in assembled AChR,
and may have important functional consequences as N-linked
glycosylation significantly affects AChR channel function and
surface expression (Gehle et al., 1997; Ramanathan and Hall,
1999; Nishizaki, 2003; Dellisanti et al., 2007). Interestingly,
a different form of Golgi-based quality control was recently
demonstrated for the neuronal AChR, where receptors with
α3β4α5 stoichiometry were found to be selectively recognized
in the Golgi and recycled, whilst (α3)2(β4)3 receptors were
trafficked to the cell surface (Crespi et al., 2018). Together
with our current findings, this demonstrates that trafficking
of assembled AChR is regulated at the Golgi complex and
that this checkpoint governs additional aspects of AChR
biogenesis and maturation.
Finally, in addition to regulating Golgi trafficking, we
show that the MX-helix plays a role in receptor assembly.
Two CMS-linked mutations in the epsilon subunit MX-
helix (εP351L and εdel349-357) significantly reduced
surface expression of the receptor, which is likely due
to impaired α/ε heterodimer formation (Croxen et al.,
2001). Similarly, we found that the corresponding mutation
introduced into the beta subunit MX-helix (βP355L) also
FIGURE 6 | Model for role of MX-helix in AChR assembly and trafficking. Our
findings identify two molecular signals in the AChR subunit MX-helix that
regulate receptor assembly and trafficking. First, shared determinants near the
end of the MX-helix contribute to receptor assembly in the ER. Second,
specific determinants in the β (green) and δ (blue) subunit MX-helix regulate
Golgi trafficking and quality control by: (i) retention of incorrectly assembled
subunits that escape endoplasmic reticulum associated protein degradation
(ERAD), which leads to their ubiquitination and degradation; and (ii) transient
retention of assembled AChR, which facilitates the modification of N-linked
glycosylation (oligosaccharides depicted in blue). The molecular basis for the
two forms of quality control could stem from the motifs being exposed in
incorrectly assembled receptor (red MX-helix), but being masked or regulated
in assembled receptor (black and orange MX-helices). The identity of the
Golgi-resident protein that binds the motifs (orange L) remains unknown.
reduced AChR levels by inhibiting β subunit assembly,
as did a βL354K mutation predicted to misposition the
MX-helix. Notably, these mutations lie at the end of the
MX-helix, which in the α4β2 crystal structure contacts
the short loop following TM3 in the adjacent subunit.
In addition, the end of the MX-helix may facilitate the
correct folding of the following residues, which were not
resolved in the crystal structure, but could also contribute
to the interface between adjacent subunits. Consequently,
these mutations likely directly disrupt subunit recognition
and assembly, although we cannot discount the possibility
that they perturb subunit folding and indirectly inhibit
subunit assembly. These findings suggest, therefore,
that shared determinants in the subunit MX-helices
contribute to subunit assembly and are important for AChR
surface expression.
In summary, we define roles for the MX-helix in both
AChR subunit assembly and Golgi trafficking and quality
control. These functions are potentially linked as shown
in our working model in Figure 6. We propose that
incorrect or incomplete assembly of receptor subunits
mispositions the MX-helix and exposes the retention signals,
leading to their ubiquitination and sorting into degradative
pathways. In contrast, correct assembly of receptor subunits
positions the MX-helix so that the retention motifs are
partially masked or regulated, and thereby allows forward
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trafficking of the AChR. Together with earlier ER-based quality
control mechanisms, this would ensure that only correctly
assembled – fully functional – AChR is trafficked to the muscle
plasma membrane and localized at the NMJ.
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